Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Haviland, Rachel ^a   Eschrich, Steven ^a   Bloom, Gregory ^a   Ma, Yihong ^a   Minton, Susan ^a   Jove, Richard ^b   Cress, W Douglas ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; NECDIN; SMALL INTERFERING RNA; STAT3 PROTEIN; NERVE PROTEIN; NUCLEAR PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE REPRESSION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE BINDING SITE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROMOTER REGION; PROSTATE CANCER; PROTEIN DNA BINDING; BINDING SITE; DNA MICROARRAY; GENETIC TRANSCRIPTION; GENETICS; HUMAN GENOME; METABOLISM; PHYSIOLOGY;

BINDING SITES; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; NEOPLASMS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 80055051714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024923     Document Type: Article

References (66)

1. Darnell JE Jr, (1997) STATs and gene regulation. Science 277: 1630-1635.
2. Darnell JE Jr, Kerr IM, Stark GR, (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421.
3. Leaman DW, Leung S, Li X, Stark GR, (1996) Regulation of STAT-dependent pathways by growth factors and cytokines. Faseb J 10: 1578-1588.
4. Levy DE, Darnell JE Jr, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
5. Yu H, Jove R, (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105.
6. Zhang YW, Wang LM, Jove R, Vande Woude GF, (2002) Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21: 217-226.
7. Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, et al. (2002) Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 277: 30716-30723.
8. Bowman T, Garcia R, Turkson J, Jove R, (2000) STATs in oncogenesis. Oncogene 19: 2474-2488.
9. Bromberg J, Darnell JE Jr, (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.
10. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
11. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, et al. (1998) Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 102: 1385-1392.
12. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97: 4227-4232.
13. Ni Z, Lou W, Leman ES, Gao AC, (2000) Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228.
14. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, et al. (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59: 5059-5063.
15. Garcia R, Bowman TL, Niu G, Yu H, Minton S, et al. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513.
16. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, et al. (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111: 1515-1523.
17. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
18. Qiu Z, Huang C, Sun J, Qiu W, Zhang J, et al. (2007) RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci 98: 1099-1106.
19. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54.
20. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, et al. (2007) Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5: 823-832.
21. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, et al. (1998) STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 78: 326-330.
22. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, et al. (2000) Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19: 5419-5427.
23. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19.
24. Snyder M, Huang XY, Zhang JJ, (2008) Identification of novel direct Stat3 target genes for control of growth and differentiation. J Biol Chem 283: 3791-3798.
25. Paz K, Socci ND, van Nimwegen E, Viale A, Darnell JE, (2004) Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA. Oncogene 23: 8455-8463.
26. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408.
27. Sekkai D, Gruel G, Herry M, Moucadel V, Constantinescu SN, et al. (2005) Microarray analysis of LIF/Stat3 transcriptional targets in embryonic stem cells. Stem Cells 23: 1634-1642.
28. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, et al. (2005) Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 65: 5054-5062.
29. Maruyama K, Usami M, Aizawa T, Yoshikawa K, (1991) A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells. Biochem Biophys Res Commun 178: 291-296.
30. Aizawa T, Maruyama K, Kondo H, Yoshikawa K, (1992) Expression of necdin, an embryonal carcinoma-derived nuclear protein, in developing mouse brain. Brain Res Dev Brain Res 68: 265-274.
31. Hayashi Y, Matsuyama K, Takagi K, Sugiura H, Yoshikawa K, (1995) Arrest of cell growth by necdin, a nuclear protein expressed in postmitotic neurons. Biochem Biophys Res Commun 213: 317-324.
32. Uetsuki T, Takagi K, Sugiura H, Yoshikawa K, (1996) Structure and expression of the mouse necdin gene. Identification of a postmitotic neuron-restrictive core promoter. J Biol Chem 271: 918-924.
33. Chapman EJ, Knowles MA, (2009) Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinog 48: 975-981.
34. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, et al. (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8: 1267-1276.
35. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, et al. (2000) Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 275: 24935-24944.
36. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. Cell 98: 295-303.
37. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
38. Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, et al. (2002) Small changes in expression affect predisposition to tumorigenesis. Nat Genet 30: 25-26.
39. Odajima J, Matsumura I, Sonoyama J, Daino H, Kawasaki A, et al. (2000) Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. J Biol Chem 275: 24096-24105.
40. Frame MC, (2004) Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117: 989-998.
41. Frame MC, (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602: 114-130.
42. Brunton VG, Frame MC, (2008) Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 8: 427-432.
43. Puthier D, Bataille R, Amiot M, (1999) IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29: 3945-3950.
44. Niu G, Wright KL, Ma Y, Wright GM, Huang M, et al. (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25: 7432-7440.
45. Saura M, Zaragoza C, Bao C, Herranz B, Rodriguez-Puyol M, et al. (2006) Stat3 mediates interleukin-6 [correction of interelukin-6] inhibition of human endothelial nitric-oxide synthase expression. J Biol Chem 281: 30057-30062.
46. Gao SP, Bromberg JF, (2006) Touched and moved by STAT3. Sci STKE 2006: pe30.
47. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
48. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
49. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, et al. (2001) DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276: 6675-6688.
50. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83.
51. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, et al. (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64: 5270-5282.
52. Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I, (2007) Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 5: 1331-1341.
53. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, et al. (2004) Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3: 1533-1542.
54. Giri D, Ozen M, Ittmann M, (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165.
55. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP, (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133.
56. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC, (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42: 239-242.
57. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, et al. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666.
58. Okamoto M, Lee C, Oyasu R, (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141-146.
59. Taniura H, Taniguchi N, Hara M, Yoshikawa K, (1998) Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem 273: 720-728.
60. Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, et al. (2005) Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14: 925-932.
61. Darnell JE Jr, (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749.
62. Turkson J, (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8: 409-422.
63. Turkson J, Jove R, (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626.
64. Buettner R, Mora LB, Jove R, (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954.
65. Johnson PJ, Coussens PM, Danko AV, Shalloway D, (1985) Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol Cell Biol 5: 1073-1083.
66. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.